TerminatedNCT01615185
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia
Medication studyAges 18–55Taiwan
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Kaohsiung CitySee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 96
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01615185
- Official title
Show the full official title
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia
Recruitment & locations
TerminatedKaohsiung City
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Kaohsiung Kai-Suan Psychiatric Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including full-dose amisulpride.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
